Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

April 10, 2024

https://www.prnewswire.com/news-releases/compugen-publishes-paper-in-cancer-immunology-research-demonstrating-therapeutic-potential-of-com503-302112780.html

HOLON, Israel, April 10, 2024 /PRNewswire/ — Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled ‘Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects’ link, in Cancer Immunology Research, a journal of the American Association for Cancer Research with a presentation at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.